Scarica l'app Stockscreener
25.00
0.16%
-0.04
Dopo l'orario di chiusura:
25.36
0.36
+1.44%
Precedente Chiudi:
$25.04
Aprire:
$24.95
Volume 24 ore:
232.62K
Relative Volume:
0.71
Capitalizzazione di mercato:
$1.62B
Reddito:
-
Utile/perdita netta:
$-143.59M
Rapporto P/E:
-8.8539
EPS:
-2.8236
Flusso di cassa netto:
$-119.47M
1 W Prestazione:
-9.91%
1M Prestazione:
-1.38%
6M Prestazione:
+39.04%
1 anno Prestazione:
+34.84%
Intervallo 1D:
$24.36
$25.99
Intervallo di 1 settimana:
$23.62
$28.43
Portata 52W:
$11.51
$29.80
Pharvaris Nv Stock (PHVS) Company Profile
Confronta PHVS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
25.00 | 1.63B | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-15 | Iniziato | H.C. Wainwright | Buy |
| 2025-10-09 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-06-11 | Iniziato | Guggenheim | Buy |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-09-25 | Iniziato | Wedbush | Outperform |
| 2023-08-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | Iniziato | Bryan Garnier | Buy |
| 2022-09-13 | Ripresa | JMP Securities | Mkt Outperform |
| 2022-08-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-05-25 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-03-02 | Iniziato | BofA Securities | Neutral |
| 2021-03-02 | Iniziato | Morgan Stanley | Overweight |
| 2021-03-02 | Iniziato | Oppenheimer | Outperform |
| 2021-03-02 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Pharvaris Nv Borsa (PHVS) Ultime notizie
Why Pharvaris N.V. stock attracts high net worth investorsMarket Rally & Reliable Price Breakout Signals - ulpravda.ru
Why Pharvaris N.V. stock remains a top recommendationOil Prices & Real-Time Market Sentiment Reports - ulpravda.ru
Will Pharvaris N.V. (9EN) stock split increase liquidity2025 Year in Review & Capital Efficient Trade Techniques - ulpravda.ru
Street Watch: Why Pharvaris N.V. stock remains a top recommendationDay Trade & Daily Entry Point Trade Alerts - ulpravda.ru
How Pharvaris N.V. (9EN) stock reacts to fiscal policiesJuly 2025 PreEarnings & Low Volatility Stock Suggestions - ulpravda.ru
How Pharvaris N.V. stock responds to policy changes2025 Market Outlook & Real-Time Volume Trigger Notifications - ulpravda.ru
Pharvaris (NASDAQ:PHVS) Shares Down 5.7%What's Next? - MarketBeat
LongTerm Outlook Is Uravi Defence and Technology Limited a BuyandHold StockEarnings Volatility Patterns & Low Cost Stock Ideas - earlytimes.in
CEO Moves: Is Pharvaris NV stock trading near support levelsMarket Performance Report & High Conviction Buy Zone Alerts - moha.gov.vn
Pharvaris (NASDAQ:PHVS) Raised to “Hold” at Wall Street Zen - Defense World
Trading the Move, Not the Narrative: (PHVS) Edition - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Trading 3.8% Higher – What’s Next? - Defense World
Pharvaris N.V. (PHVS) Stock Analysis: Assessing a 66.61% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Pharvaris (NASDAQ:PHVS) Shares Up 3.8%Should You Buy? - MarketBeat
Aug Retail: How Pharvaris NV stock responds to policy changesJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - moha.gov.vn
Pharvaris N.V. (NASDAQ:PHVS) Sees Large Increase in Short Interest - MarketBeat
Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Pharvaris (NASDAQ:PHVS) Shares Down 6.9%Time to Sell? - MarketBeat
Why Pharvaris (PHVS) Is Up 13.3% After RAPIDe-3 Success And 2026 Deucrictibant Filing Plans - Sahm
Behavioral Patterns of PHVS and Institutional Flows - Stock Traders Daily
Pharvaris N.V.(NasdaqGS: PHVS) added to NASDAQ Biotechnology Index - marketscreener.com
What Does Wall Street Think About Pharvaris N.V. (PHVS)? - Insider Monkey
Sentiment Recap: Is Pharvaris NV 9EN stock at risk of policy regulationQuarterly Growth Report & Consistent Return Investment Signals - moha.gov.vn
Why analysts upgrade Pharvaris N.V. stockJuly 2025 Macro Moves & Safe Entry Trade Reports - Улправда
Is Pharvaris N.V. stock trading near support levelsWeekly Volume Report & Risk Managed Investment Signals - DonanımHaber
Aug Final Week: Why analysts upgrade Pharvaris N.V. stockExit Point & Reliable Entry Point Trade Alerts - Улправда
Is Pharvaris N.V. (9EN) stock a momentum leaderJuly 2025 Final Week & Short-Term Trading Opportunity Alerts - Улправда
How geopolitical tensions affect Pharvaris N.V. stockJuly 2025 Opening Moves & Weekly Breakout Watchlists - Улправда
Total debt per share of Pharvaris N.V. – MUN:9EN - TradingView — Track All Markets
Pharvaris (PHVS) Is Down 5.7% After Pivotal RAPIDe-3 Deucrictibant Data And 2026 Filing Plan - Sahm
Pharvaris (NASDAQ:PHVS) Rating Lowered to Sell at Wall Street Zen - Defense World
Pharvaris N.V. $PHVS Shares Bought by TFG Asset Management GP Ltd - MarketBeat
(PHVS) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary AngioedemaSlideshow (NASDAQ:PHVS) 2025-12-09 - Seeking Alpha
This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? - AOL.com
Pharvaris’ Deucrictibant Provides Rapid Relief for HAE in Phase 3 RAPIDe-3 Trial - HCPLive
Pharvaris stock gains on HAE drug meeting late-stage study goals - MSN
GENERAL ATLANTIC, L.P.'s Pharvaris NV(PHVS) Holding History - GuruFocus
Pharvaris (PHVS): Reassessing Valuation After Strong RAPIDe-3 Phase 3 Success in Hereditary Angioedema - Sahm
Pharvaris N.V. (PHVS) Price Target Increased by 20.90% to 45.73 - Nasdaq
Pharvaris (NASDAQ:PHVS) Given New $30.00 Price Target at Bank of America - MarketBeat
Why Pharvaris N.V. (9EN) stock could outperform next year2025 Retail Activity & Free Daily Entry Point Trade Alerts - Newser
Pharvaris (NASDAQ:PHVS) Price Target Raised to $30.00 at Bank of America - Defense World
B of A Securities Maintains Pharvaris N.V. (PHVS) Neutral Recommendation - Nasdaq
Guggenheim Maintains Pharvaris N.V. (PHVS) Buy Recommendation - Nasdaq
Oppenheimer Maintains Pharvaris N.V. (PHVS) Outperform Recommendation - Nasdaq
Officer Abele Files To Sell 4,109 Of Pharvaris NV [PHVS] - TradingView
Pharvaris N.V. (PHVS) Presents at BSI Clinical Immunology Professional Network (BSI-CIPN) Conference 2025Slideshow (NASDAQ:PHVS) 2025-12-04 - Seeking Alpha
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals - sharewise.com
Is Pharvaris N.V. stock undervalued vs historical averagesWeekly Market Report & Safe Capital Growth Tips - Newser
Pharvaris Nv Azioni (PHVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):